Are excipients really inert ingredients? A review of adverse reactions to excipients in oral dermatologic medications in Canada

Journal of Cutaneous Medicine and Surgery

Volumn 14, Issue 3, 2010, Pages 105-114

  Noiles, Kristin ^a   Vender, Ronald ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBENZOIC ACID ESTER; ALCOHOL; ARACHIS OIL; BENZOIC ACID DERIVATIVE; CELLULOSE DERIVATIVE; COLORING AGENT; DERMATOLOGICAL AGENT; DRUG PRESERVATIVE; DYE; FLAVORING AGENT; GELATIN; GLUTEN; LACTOSE; MACROGOL; SOYBEAN OIL; STARCH; SULFITE; SWEETENING AGENT; TARTRAZINE; EXCIPIENT; PRESERVATIVE;

ACCURACY; CANADA; EXCIPIENT COMPATIBILITY; HUMAN; HYPERSENSITIVITY REACTION; ORAL DRUG ADMINISTRATION; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; CHEMISTRY; MEDICINAL CHEMISTRY;

CANADA; CHEMISTRY, PHARMACEUTICAL; COLORING AGENTS; DERMATOLOGIC AGENTS; EXCIPIENTS; HUMANS; LACTOSE; PRESERVATIVES, PHARMACEUTICAL; SULFITES; SWEETENING AGENTS;

EID: 77952947494     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2010.09027     Document Type: Review

References (127)

1. Steinberg M, Borzelleca JF, Enters EK, et al. A new approach to the safety of assessment of pharmaceutical excipients. Regul Toxicol Pharm 1996;24:149-154 (Pubitemid 26400649)
2. Pifferi G, Santoro P, Pedrani M. Quality and functionality of excipients. Farmaco 1999;54:1-14.
3. Pifferi G, Restani P. The safety of pharmaceutical excipients. Farmaco 2003;58:541-550
4. Baldrick P. Pharmaceutical excipient development: the need for preclinical guidance. Regul Toxicol Pharm 2000;32:210-218
5. Smith JM, Dodd TRP. Adverse reactions to pharmaceutical excipients. Adv Drug React Ac Pois Rev 1982;1:93-142.
6. Weiner M, Bernstein IL. Adverse reactions to drug formulation agents: a handbook of excipients. New York: Marcel Dekker; 1989.
7. Kumar A, Rawlings RD, Beaman DC. The mystery ingredients: sweeteners, flavorings, dyes, and preservatives in analgesic/antipyretic, antihistamine/decongestant, cough and cold, antidiarrheal, and liquid theophylline preparations. Pediatrics 1993; 91:927-933
8. Pawar S, Kumar A. Issues in the formulation of drugs for oral use in children: role of excipients. Pediatr Drugs 2002;4:371-379 (Pubitemid 34651926)
9. Kumar A, Weatherly MR, Beaman DC. Sweeteners, flavorings, and dyes in antibiotic preparations. Pediatrics 1991;87:352-360
10. Barbaud AB. Place of excipients in drug-related allergy. Clin Rev Allergy Immunol 1995;13:253-263
11. American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update. Pediatrics 1997; 99:268-278
12. Kumar A, Aitas AT, Hunter AG, et al. Sweeteners, dyes, and other excipients in vitamin and mineral preparations. Clin Pediatr (Phila) 1996;35:443.
13. Simon RA. Adverse reactions to drug additives. J Allergy Clin Immunol 1984;74:623-630
14. Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties (CPS). Ottawa, ON: Canadian Pharmacists Association; 2008.
15. Michaelsson G, Juhlin L. Urticaria induced by preservatives and dye additives in food and drugs. Br J Dermatol 1973;88:525.
16. Weber R, Hoffman M, Raine D, et al. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in population of perennial asthmatics. J Allergy Clin Immunol 1979;64:32-37 (Pubitemid 10161629)
17. Juhlin L, Michaëlsson G, Zetterström O. Urticaria and asthma induced by food-and-drug additives in patients with aspirin hypersensitivity. J Allergy Clin Immunol 1972;50:92-98
18. Michaelsson G, Pettersson L, Juhlin L. Purpura caused by food and drug additives. Arch Dermatol 1974;109:49-52.
19. Desmond RE, Trautlein JJ. Tartrazine (FD&C yellow #5) anaphylaxis: a case report. Ann Allergy 1981;46:81-82 (Pubitemid 11090476)
20. Hariparsad D, Wilson N, Dixon N, et al. Oral tartrazine challenge in childhood asthma: effect on bronchial reactivity. Clin Allergy 1984;14:81-85 (Pubitemid 14219754)
21. Trautlein JJ, Mann WJ. Anaphylactic shock caused by yellow dye (FD&C #5 and FD&C #6) in an enema (case report). Ann Allergy 1978;41:28-29
22. Lockey SD. Hypersensitivity to tartrazine (FD&C yellow #5) and other dyes in additives present in food and pharmaceutical products. Ann Allergy 1977;38:206-210
23. Lockey SD. Reactions to hidden agents in foods, beverages and drugs. Ann Allergy 1971;29:461-466
24. Ram FS, Arden KD. Tartrazine exclusion for allergic asthma. Cochrane Database Syst Rev 2001;(4) CD 000460.
25. Criep LH. Allergic vascular purpura. J Allergy 1971;48:7-12.
26. Parodi G, Parodi A, Rebora A. Purpuric vasculitis due to tartrazine. Dermatologica 1985;171:62-63
27. Settipane GA, Chafee FH, Postman IM, et al. Significance of tartrazine sensitivity in chronic urticaria of unknown etiology. J Allergy Clin Immunol 1976;57:541-546
28. Stenius RSM, Lemola M. Hypersensitivity of acetylsalicylic acid (ASA) and tartrazine in patients with asthma. Clin Allergy 1976;6: 119-129
29. Chafee FH, Settipane GA. Asthma caused by FD&C approved dyes. J Allergy 1967;40:65-72.
30. Settipane GA, Pudupakkam RK. Aspirin intolerance. III. Subtypes, familial occurrence, and cross-reactivity with tartrazine. J Allergy Clin Immunol 1975;56:215-221
31. Samter M, Beers RF. Concerning the nature of intolerance to aspirin. J Allergy 1967;40:281-293
32. Food Drug Administration. Yellow No. 5 (tartrazine) labeling on drugs to be required. FDA Drug Bull 1979;9:18.
33. MacCara ME. Tartrazine: a potentially hazardous dye in Canadian drugs. Can Med Assoc J 1982;126:910-914
34. Supramaniam G, Warner JO. Artificial food additive intolerance in patients with angio-edema and urticaria. Lancet 1986;2:907-909 (Pubitemid 17170653)
35. Chafee FH, Settipane GA. Asthma caused by FD&C approved dyes. J Allergy 1967;40:65-72.
36. Weber R, Hoffman M, Raine D, et al. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in population of perennial asthmatics. J Allergy Clin Immunol 1979;64:32-37 (Pubitemid 10161629)
37. Bell T. Colourants and drug reactions. Lancet 1991;338:55-56
38. Koppel BS, Harden CL, Daras M. Tegretol excipient-induced allergy. Arch Neurol 1991;48:789.
39. Vesely B, Bodmer R, Guerin B, et al. Manifestations cliniques à l'érythrosine: étude du rôle des mécanismes d'hypersensibilité. Rev Fr Allergol 1985;25:7-11.
40. Haas S. Contamination of protein-bound iodine by pink gelatin capsules colored with erythrosine. Ann Intern Med 1970;72:549-552
41. Sasseville D, Joncas V. Allergic contact cheilitis from D & C Yellow 11. Contact Dermatitis 2009;60:294-295
42. Larsen WG. Cosmetic dermatitis due to a dye (D and C Yellow # 11). Contact Dermatitis 1975;1:61.
43. Calnan CD. Quinazoline yellow SS in cosmetics. Contact Dermatitis 1976;2:160-166
44. Sarkany I, Meara RH, Everall J. Cheilitis due to carmine in lip salve. Trans St Johns Hosp Dermatol Soc 1961;46:39-40.
45. DiCello MC, Myc A, Baker JR, et al. Anaphylaxis after ingestion of carmine colored foods: two case reports and a review of the literature. Allergy Asthma Proc 1999;20:377-382
46. Kwiterovich KA, Maguire MG, Murphy RP, et al. Frequency of adverse reactions after fluorescein angiography. Ophthalmology 1991;98:1139-1142
47. Lipson BK, Yannuzzi LA. Complications of intravenous fluorescein injections. Int Ophthalmol Clin 1989;29:200-205
48. Feingold BF. Hyperkinesis and learning disabilities linked to artificial food flavors and colors. Am J Nurs 1975;75:797-803.
49. Bellisle F. Effects of diet on behaviour and cognition in children. Br J Nurs 2004;92 Suppl 2:S227-32.
50. Ortolani C, Bruijnzeel-Koomen C, Bengstsson U, et al. Controversial aspects of adverse reactions to food. Allergy 1999; 54:27-54.
51. Adams W. Lack of behavioral effects from Feingold diet violations. Percept Mot Skills 1981;52:307-313
52. Mattes JA, Gittelman R. Effects of artificial food colorings in children with hyperactive symptoms: a critical review and results of a controlled study. Arch Gen Psychiatry 1981;38:714-718 (Pubitemid 11064829)
53. David TJ. Reactions to dietary tartrazine. Arch Dis Child 1987;62: 119-122
54. Thorley G. Pilot study to assess behavioural and cognitive effects of artificial food colours in a group of retarded children. Dev Med Child Neurol 1984;26:56-61. (Pubitemid 14220487)
55. Kavale KA, Forness SR. Hyperactivity and diet treatment: a meta-analysis of the Feingold hypothesis. J Lean Disabil 1983;16:324-330
56. Ribon A, Joshi S. Is there any relationship between food additives and hyperkinesis? Ann Allergy 1982;48:275-278
57. Mattes JA. The Feingold diet: a current reappraisal. J Learn Disabil 1983;16:319-323
58. Latronica RJ, Goldberg AF, Wightman JR. Local anesthetic sensitivity. Oral Surg 1969;28:439-441
59. Aldrete JA, Johnson DA. Allergy to local anesthetics. JAMA 1969; 207:356-357
60. Nagel JE, Fuscaldo JT, Fireman P. Paraben allergy. JAMA 1977; 237:1594-1595
61. Aeling JL, Nuss D. Systemic eczematous 'contact type' dermatitis medicamentosa caused by parabens. Arch Dermatol 1974;110:640.
62. Coloe J, Zirwas MJ. Allergens in corticosteroid vehicles. Dermatitis 2008;19:38-42.
63. Henry JC, Tschen EH, Becker LE. Contact urticaria to parabens. Arch Dermatol 1979;115:1231-1232
64. Lederman D, Freedman PD, Kerpel SM, et al. An unusual skin reaction following local anesthetic injection. Review of the literature and report of four cases. Oral Surg Oral Med Oral Pathol 1980;49:28-33.
65. Zurcher K, Krebs A. Cutaneous drug reactions. an integral synopsis of today's systemic drugs, 2nd ed. Basel (Switzerland): Karger; 1992.
66. Thomas DR, Pursley TV, Jorizzo JL. Chronic urticaria secondary to aminobenzoic acid. Arch Dermatol 1984;120:961-962
67. Osterhalle O, Taudoroff E, Hashr J. Intolerance to aspirin, food-coloring agents and food preservatives in childhood asthma. Ogeskr Laeger 1979;141:1908-1910 (Pubitemid 9210430)
68. Moneret-Vautrin DA, Moeller R, Malingrey L. Anaphylactoid reaction to general anaesthesia: a case of intolerance to sodium benzoate. Anaesth Intens Care 1982;10:156-157 (Pubitemid 12105439)
69. Kubba R, Champion R. Anaphylactoid purpura caused by tartrazine and benzoates. Br J Dermatol 1975;93:61s-2s.
70. Schwartz HJ, Sher TH. Metabisulfite sensitivity in a patient without hyperactive airway disease. Immunol Allergy Pract 1986; 8:308-311
71. Yang WH, Purchase ECR, Rivington RN. Positive skin tests and Prausnitz-Kustner reactions in metabisulfite-sensitive subjects. J Clin Allergy Immunol 1986;78:443-449
72. Sokol WN, Hydick IB. Nasal congestion, urticaria, and angioedema caused by an IgE-mediated reaction to sodium metabisulfite. Ann Allergy 1990;65:233-237
73. Simon RA. Sulfite sensitivity. Ann Allergy 1986;56:281-288
74. Dooms-Goossens A, Gidi de Alam A, Degreef H, et al. Local anesthetic intolerance due to metabisulfite. Contact Dermatitis 1989;20:124-126 (Pubitemid 19051489)
75. Wong GAE, Shear NH. Adverse drug interactions and reactions in dermatology: current issues of clinical relevance. Dermatol Clin 2005;23:335-342 (Pubitemid 40503275)
76. Knowles S, Shapiro L, Shear NH. Should celecoxib be contra-indicated in patients who are allergic to sulfonamides? Revisiting the meaning of "sulfa" allergy. Drug Saf 2001;24:239-247
77. Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy 2004;24:856-870
78. Feigal RJ, Jensen ME, Mensing CA. Dental caries potential of liquid medications. Pediatrics 1981;68:416-419 (Pubitemid 11014453)
79. Roberts FI, Robert GJ. Relation between medicines sweetened with sucrose and dental disease. Br Med J 1979;2:14-16
80. Hill EM, Flaitz CM, Frosst GR. Sweetener content of common pediatric oral liquid medications. Am J Hosp Pharm 1988;45:135-142
81. Novick N. Aspartame-induced granulomatous panniculitis. Ann Intern Med 1985;104:206-207
82. McCauliffe DP, Poitras K. Aspartame-induced lobular panniculitis. J Am Acad Dermatol 1991;24:298-300.
83. Drake ME. Panic attacks and excessive aspartame ingestion. Lancet 1986;2:631.
84. Wurtman RJ. Aspartame: possible effect on seizure susceptibility. Lancet 1985;2:1060.
85. Walton RG. Seizure and mania after high intake of aspartame. Psychosomatics 1986;27:218-220 (Pubitemid 16137350)
86. Gulya AJ, Session RB, Troost TR. Aspartame and dizziness: preliminary results of a prospective, nonblinded, prevalence and attempted cross-over study. Am J Otol 1992;13:438-442
87. Eshel Y, Sarova-Pinhas. Aspartame and seizures. Neurology 1993; 43:2154-2155
88. Gordon HH. Episodic urticaria due to saccharin ingestion. J Allergy Clin Immunol 1975;56:78-79
89. Gordon H. Untoward reactions to saccharin. Cutis 1972;10:77-81.
90. Birbeck J. Saccharin-induced skin rashes. N Z Med J 1989;102:24.
91. Butchko HH, Stargel WW, Comer CP. Aspartame: review of safety. Regul Toxicol Pharmacol 2002;35(2 Pt 2) Suppl 1:S1-93.
92. Mackey SA, Berlin CM Jr. Effect of dietary aspartame on plasma concentrations of phenylalanine and tyrosine in normal and homozygous phenylketonuric patients. Clin Pediatr 1992;31:394-399
93. Koch R, Schaeffler G, Shaw KNF. Results of loading doses of aspartame by two phenylketonuric (PKU) children compared with two normal children. J Toxicol Environ Health 1976;2:459-469 (Pubitemid 8055673)
94. Wolf-Novak LC, Stegnik LD, Brummel MC, et al. Aspartame ingestion with and without carbohydrate in phenylketonuric and normal subjects: effect on plasma concentrations of amino acids, glucose, and insulin. Metabolism 1990;39:391-396
95. Smith RJ. Aspartame approved despite risks. Science 1981;213: 986-987
96. Gunsel WC, Lachman L. Comparative evaluation of tablet formulations prepared from conventionally-processed and spray-dried lactose. J Pharm Sci 1963;52:178-182
97. Lieb J, Kazienko DJ. Lactose filler as a cause of "drug induced" diarrhea. N Engl J Med 1978;299:314.
98. Brandstetter RD, Conetta R, Glazer B. Lactose intolerance associated with Intal capsules. N Engl J Med 1986;315:1613-1614 (Pubitemid 17055402)
99. Petrini L, Usai P, Caradonna A, et al. Lactose intolerance following antithyroid drug medications. J Endocrinol Invest 1997; 20:569-570 (Pubitemid 28014511)
100. Lactose malabsorption lactose intolerance Lancet 1979;II:831-832
101. Gundend-Hower E, Dahlquist A, Jarnum S. The clinical significance of lactose malabsorption. Am J Gastroenterol 1970; 53:460-471
102. Eadala P, Waud JP, Matthews SB, et al. Quantifying the 'hidden' lactose in drugs used for the treatment of gastrointestinal conditions. Aliment Pharmacol Ther 2009;29:677-687
103. Huriez C, Agache P, Martin P. Allergy to propylene glycol. Rev Fr Allergy 1966;6:200.
104. Hannuksela M, Forstrom L. Reactions to peroral propylene glycol. Contact Dermatitis 1978;4:41-45
105. Fisher AA. Contact dermatitis from topical medications. Semin Dermatol 1982;1:49-57.
106. Fisher AA. Systemic contact dermatitis due to intravenous Valium in a person sensitive to propylene glycol. Cutis 1995;55:327-328
107. Eiermann HJ, Larsen W, Maibach HJ, et al. Prospective study of cosmetic reactions: 1977-1980. North American Contact Dermatitis Group. J Am Acad Dermatol 1982;6:909-917
108. Kelner MJ, Bailey BN. Propylene glycol as a cause of lactic acidosis. J Anal Toxicol 1985;9:40-42
109. Neale BW, Mesler EL, Young M, et al. Propylene glycol-induced lactic acidosis in a patient with normal renal function: a proposed mechanism and monitoring recommendations. Ann Pharmacother 2005;39:1732-1736 (Pubitemid 41393135)
110. Budavari S, O-Neil MJ, Smith A, et al. The Merck index - an encyclopedia of chemicals, drugs, and biological. Whitehouse Station (NJ): Merck & Co.; 1989.
111. Arroliga AC, Shehab N, McCarthy K, et al. Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults. Crit Care Med 2004;32: 1709-1714 (Pubitemid 39050522)
112. Demey HE, Daelemans RA, Verpooten GA, et al. Propylene glycol-induced side effects during intravenous nitroglycerin therapy. Intensive Care Med 1988;14:221-226
113. Martin G, Finberg L. Propylene glycol: a potentially toxic vehicle in liquid dosage form. J Pediatr 1978;93:877-878
114. Arulanantham K, Genel M. Central nervous system toxicity associated with ingestion of propylene glycol. J Pediatr 1978;93: 515-516 (Pubitemid 8384118)
115. Toxicological evaluation of oxidized starch. WHO Food Additives Serv 1974;5:365-367
116. Patterson DL, Yunginger JW, Dunn WF. Anaphylaxis induced by the carboxymethylcellulose component of injectable triamcinolone acetonide suspension (Kenalog). Ann Allergy Asthma Immunol 1995;74:163-166
117. Beaudoin E, Kanny G, Gueant JL, et al. Anaphylaxis caused by carboxymethylcellulose: report of 2 cases of shock from injectable corticoids. Allergie Immunol 1992;24:333-335
118. Bligliardi PL, Izakovic J, Webe JM. Anaphylaxis to the carbohydrate carboxymethylcellulose in parenteral corticosteroid preparations. Dermatology 2003;207:100-103
119. Rubinger D, Friendlander M, Superstine E. Hypersensitivity to tablet additives in transplant recipients on prednisone. Lancet 1978;2(8091):689. (Pubitemid 9048406)
120. Elphinstone P, Kobza, Black A, et al. Alcohol induced urticaria. J R Soc Med 1985;78:340-341
121. Crevel RWR, Kerkoff MAT, Koning MMG. Allergenicity of refined vegetable oils. Food Chem Toxicol 2000;38:385-393
122. Besler M, Steinhart H, Paschke A, et al. Stability of food allergens and allergenicity of processed foods. J Chromatogr B 2001;756: 207-228 (Pubitemid 32497066)
123. Olszewski A, Pons L, Moutete F, et al. Isolation and characterization of proteic allergens in refined peanut oil. Clin Exp Allergy 1998;28:850-859 (Pubitemid 28335563)
124. Moneret-Vautrin DA, Rance F, Kanny G, et al. Food allergy to peanuts in France-evaluation of 142 observations. Clin Exp Allergy 1998;28:1113-1119 (Pubitemid 28432634)
125. Andersen HL, Nissen I. Presumed anaphylactic shock after infusion of Lipofundin. Ugeskr Laeger 1993;115:2210-2211
126. Hiyama DT, Griggs B, Mittman RJ, et al. Hypersensitivity following liquid emulsion infusion in an adult patient. JPEN J Parenter Enteral Nutr 1989;13:318-320 (Pubitemid 19141327)
127. Bush RK, Taylor SL, Nordlee JA, et al. Soybean oil is not allergenic to soybean-sensitive individuals. J Allergy Clin Immunol 1985;76: 242-245